Global immuno-oncology assays market is estimated to be valued at USD 5.55 Bn in 2025 and is expected to exhibit a CAGR of 11.4% during the forecast period (2025-2032). Immuno-oncology assays help analyze the expression of biomolecules like proteins that are relevant for cancer immunotherapies. These assays aid in tumor profiling, treatment strategies, and development of immunotherapies. They help evaluate expression of immune biomarkers, which provides crucial insights into cancer-immune interactions and offers direction for targeted therapies. Advancements in fields like proteomics, genomic analysis, and multiplex technologies have enabled development of high-throughput immuno-oncology assays. Their ability to gauge pre-existing antitumor immune responses and predict treatment outcomes makes them integral tools in precision oncology.
Market Dynamics:
The global immuno-oncology assays market growth is driven by factors such as growing demand for targeted cancer therapies, rising adoption of combinational immunotherapies, increasing R&D investments by pharmaceutical companies, and improving availability of companion diagnostic tests. However, the market faces restraints in terms of high costs associated with immuno-oncology assays and limited reimbursement for such tests. Meanwhile, ongoing research on biomarkers and development of affordable immuno-oncology assays present significant opportunities for market players.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook